

Resource Summary Report

Generated by PRECISE-TBI on Aug 16, 2026

CD3

RRID:AB_2738781

Type: Antibody

Proper Citation

BD Biosciences Cat# 564380, RRID:AB_2738781

Antibody Information

URL: http://antibodyregistry.org/AB_2738781

Proper Citation: BD Biosciences Cat# 564380, RRID:AB_2738781

Target Antigen: CD3

Host Organism: rat

Clonality: monoclonal

Comments: Flow cytometry

Antibody Name: CD3

Description: This monoclonal targets CD3

Target Organism: mouse

Clone ID: 17A2

Antibody ID: AB_2738781

Vendor: BD Biosciences

Catalog Number: 564380

Record Creation Time: 20250820T071254+0000

Record Last Update: 20250821T015106+0000

Ratings and Alerts

No rating or validation information has been found for CD3.

No alerts have been found for CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Vendramin R, et al. (2026) Nonsense-mediated mRNA decay inhibition reshapes the cancer immunoepitome. *Immunity*, 59(5), 1398.

Ai D, et al. (2026) Depletion of CX3CR1+ macrophages results in disrupted functionality and immune surveillance within epididymis and testis. *Mucosal immunology*, 19(2), 1889.

Anastacio Da Costa Carvalho L, et al. (2026) RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma. *Cancer immunology research*, 14(1), 90.

Lanzar ZR, et al. (2025) IL-27 promotes Treg cell expression of CD122 and fitness at homeostasis. *Proceedings of the National Academy of Sciences of the United States of America*, 122(50), e2519141122.

Niu D, et al. (2025) Local delivery of IL-15 and anti-PD-L1 nanobody by in vitro-transcribed circILNb elicits superior antitumor immunity in cold tumors. *Cell reports. Medicine*, 6(10), 102413.

Galvez-Cancino F, et al. (2025) Regulatory T cell depletion promotes myeloid cell activation and glioblastoma response to anti-PD1 and tumor-targeting antibodies. *Immunity*, 58(5), 1236.

Vidal SJ, et al. (2025) Mining the CD4 antigen repertoire for next-generation tuberculosis vaccines. *Cell*.

Eberhard JN, et al. (2025) Immune targeting and host-protective effects of the latent stage of *Toxoplasma gondii*. *Nature microbiology*, 10(4), 992.

Lanzar ZR, et al. (2025) De-coupling immune parameters and toxicity associated with IL-12 agonism. *Cell reports*, 44(6), 115840.

Nagai M, et al. (2024) Sugar and arginine facilitate oral tolerance by ensuring the functionality of tolerogenic immune cell subsets in the intestine. *Cell reports*, 43(7), 114490.

Rwandamuriye FX, et al. (2023) A surgically optimized intraoperative poly(I:C)-releasing hydrogel prevents cancer recurrence. *Cell reports. Medicine*, 4(7), 101113.

Garcia-Diaz C, et al. (2023) Glioblastoma cell fate is differentially regulated by the microenvironments of the tumor bulk and infiltrative margin. *Cell reports*, 42(5), 112472.

Hong JY, et al. (2020) Long-Term Programming of CD8 T Cell Immunity by Perinatal Exposure to Glucocorticoids. *Cell*, 180(5), 847.

Łedzińska A, et al. (2020) Regulatory T Cells Restrain Interleukin-2- and Blimp-1-Dependent Acquisition of Cytotoxic Function by CD4⁺ T Cells. *Immunity*, 52(1), 151.

Yen WF, et al. (2019) Distinct Requirements of CHD4 during B Cell Development and Antibody Response. *Cell reports*, 27(5), 1472.

Lalwani A, et al. (2019) Hypoxia-Inducible Factor-1 Is Required for the Prevention of Type 1 Diabetes. *Cell reports*, 27(8), 2370.